Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Coherus BioSciences, Inc.
  6. News
  7. Summary
    CHRS   US19249H1032

COHERUS BIOSCIENCES, INC.

(CHRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Coherus BioSciences : Barclays Adjusts Price Target on Coherus BioSciences to $24 From $28, Maintains Overweight Rating

05/17/2021 | 06:48am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about COHERUS BIOSCIENCES, INC.
05/24TRANSCRIPT : Coherus BioSciences, Inc. Presents at UBS Global Healthcare Conference, May-2..
CI
05/20COHERUS BIOSCIENCES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/20Coherus Biosciences, Inc. Ratifies Selection of Ernst & Young LLP as the Independent Re..
CI
05/20Mizuho Securities Cuts Price Target on Coherus BioSciences to $25 From $30, Reiterates ..
MT
05/13COHERUS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/12TRANSCRIPT : Coherus BioSciences, Inc. Presents at Bank of America 2022 Healthcare Confere..
CI
05/11Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors
GL
05/11Coherus BioSciences Appoints Jill O’Donnell-Tormey to Its Board of Directors, Nomi..
CI
05/11Blow to Roche's cancer immunotherapy prospects as 2nd trial fails
RE
05/10COHERUS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Analyst Recommendations on COHERUS BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 257 M - -
Net income 2022 -278 M - -
Net Debt 2022 239 M - -
P/E ratio 2022 -2,25x
Yield 2022 -
Capitalization 594 M 594 M -
EV / Sales 2022 3,24x
EV / Sales 2023 2,02x
Nbr of Employees 346
Free-Float 87,2%
Chart COHERUS BIOSCIENCES, INC.
Duration : Period :
Coherus BioSciences, Inc. Technical Analysis Chart | CHRS | US19249H1032 | MarketScreener
Technical analysis trends COHERUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 7,67 $
Average target price 20,43 $
Spread / Average Target 166%
EPS Revisions
Managers and Directors
Denny M. Lanfear Chairman, President & Chief Executive Officer
McDavid Stilwell Chief Financial Officer
Vladimir Vexler Chief Scientific Officer
Richard L. Hameister Chief Technical Officer
Rosh Dias Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
COHERUS BIOSCIENCES, INC.-51.94%594
GILEAD SCIENCES, INC.-11.38%80 715
REGENERON PHARMACEUTICALS, INC.8.63%73 916
VERTEX PHARMACEUTICALS22.26%68 665
WUXI APPTEC CO., LTD.-22.20%40 017
BIONTECH SE-40.07%37 546